PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Canada.\', \'School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.\', \'Lunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital, Sinai Health System, Toronto, Canada.\', \'Department of Molecular Genetics, University of Toronto, Toronto, Canada.\', \'Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.\', \'National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.\', \'Microbiology Department, Canadian Blood Services, Ottawa, Canada.\', \'Division of Diagnostic and Applied Microbiology, Department of Laboratory Medicine & Pathology, University of Alberta, Edmonton, Canada.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1371/journal.pone.0257743
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 34555095
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
?:title
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all